VBL Therapeutics to Present Complete Phase 2 Data on VB111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference

Press/Media: Press / Media

PeriodSep 17 2015

Media coverage

1

Media coverage

  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date9/17/15
    PersonsAndrew Brenner